"FDA-approved peptides" is the search term — and the answer most pages give is wrong, vague, or evasive. Some sites imply nothing is approved. Others imply everything sold under a peptide label is. Both are wrong.
The honest answer: a specific list of peptide drugs has full FDA approval for specific indications. A larger universe of compounded peptide preparations is legally prescribed in the United States but is not FDA-approved as a product. The two are different regulatory categories, both legitimate, and the distinction matters for anyone choosing therapy.
This page is the reference list. It covers what the FDA has actually approved, why the compounded category exists alongside it, and what the language on a prescription label means in 2026.
What "FDA-approved" actually means
FDA approval is drug-and-indication specific. When a sponsor seeks approval, they file a New Drug Application (NDA) or Biologics License Application (BLA) for a specific molecule, in a specific formulation, for a specific indication, supported by clinical trials. The agency reviews the chemistry, manufacturing controls, and clinical evidence. If approved, the drug carries a labeled indication, a labeled dose range, and a labeled population.
Two implications follow. First, a drug can be approved for one indication and used off-label for another — and off-label prescribing is legal and routine in US practice. Second, a drug that is approved as a brand-name product is not the same regulatory entity as a compounded preparation containing the same active ingredient. The active molecule may be identical; the regulatory pathway is not.
Peptides — short chains of amino acids, typically under 50 residues — sit inside this same framework. There is no separate "peptide approval" track. A peptide drug that wins approval is approved as a drug, the same way any small molecule or biologic is.
The actual list of FDA-approved peptide drugs (2026)
The peptides below are FDA-approved as branded products for the indications listed. Generic and authorized-generic versions exist for several. This list is therapeutic peptides used in mainstream clinical practice; it is not a complete catalog of every peptide-class molecule ever approved.
Metabolic and endocrine
Semaglutide — A glucagon-like peptide-1 (GLP-1) receptor agonist. Approved as a once-weekly subcutaneous injection for type 2 diabetes (sponsor's brand approved 2017) and for chronic weight management in adults with obesity or overweight plus a comorbidity (approved 2021). An oral formulation is approved for type 2 diabetes. Pivotal weight-management trials reported approximately 14.9% mean body-weight reduction at the 2.4 mg weekly dose over 68 weeks.1
Tirzepatide — A dual GIP/GLP-1 receptor agonist. Approved for type 2 diabetes (2022) and for chronic weight management (2023). Pivotal weight-management trials reported up to approximately 20.9% mean body-weight reduction at the highest dose tier over 72 weeks.2 Once-weekly subcutaneous injection.
Liraglutide — A GLP-1 receptor agonist administered as a once-daily subcutaneous injection. Approved for type 2 diabetes (2010) and for chronic weight management at a higher dose (2014).
Exenatide — A GLP-1 receptor agonist for type 2 diabetes, available as twice-daily and once-weekly formulations. Approved 2005 (twice-daily) and 2012 (once-weekly).
Dulaglutide — Once-weekly GLP-1 receptor agonist for type 2 diabetes, approved 2014.
Lixisenatide — Once-daily GLP-1 receptor agonist for type 2 diabetes, approved 2016.
Insulin (and its analogs) — Insulin is a peptide hormone, and modern insulin analogs are FDA-approved peptide drugs in their own right. They are not usually marketed as "peptide therapy" in the consumer sense, but they belong on a complete list.
Glucagon (recombinant) — Approved for severe hypoglycemia in patients with diabetes. Available as injection and intranasal powder.
Teduglutide — A GLP-2 analog approved for short bowel syndrome (2012). Subcutaneous daily injection.
Growth and pituitary axis
Sermorelin acetate — A growth hormone-releasing hormone (GHRH) analog. Originally approved (Geref, Geref Diagnostic) for diagnosis and treatment of growth hormone deficiency in pediatric patients. The branded products were withdrawn from the market by their sponsors — the FDA's records indicate the withdrawal was not for reasons of safety or effectiveness. Sermorelin remains available through compounding pharmacies under valid prescription.
Tesamorelin — A GHRH analog approved (2010) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
Octreotide acetate — A somatostatin analog approved for acromegaly, carcinoid syndrome, and VIPomas. Available as immediate-release subcutaneous injection and long-acting depot.
Lanreotide — A long-acting somatostatin analog approved for acromegaly and certain neuroendocrine tumors.
Pasireotide — A somatostatin analog approved for Cushing's disease and acromegaly.
Pegvisomant — A growth hormone receptor antagonist (a modified peptide) approved for acromegaly.
Reproductive and sexual health
Bremelanotide — A melanocortin receptor agonist approved (2019) for hypoactive sexual desire disorder (HSDD) in premenopausal women. Branded as Vyleesi. Subcutaneous as-needed injection.
Goserelin — A GnRH agonist (depot implant) approved for prostate cancer, breast cancer, endometriosis, and assisted reproduction.
Leuprolide — A GnRH agonist with multiple approved indications including prostate cancer, endometriosis, central precocious puberty, and uterine fibroids. Several depot formulations.
Cetrorelix and Ganirelix — GnRH antagonists approved for use in assisted reproduction protocols.
Oxytocin — Approved for induction and augmentation of labor, control of postpartum bleeding.
Carbetocin — Long-acting oxytocin analog approved for prevention of postpartum hemorrhage in some markets.
Cardiovascular and other
Eptifibatide — A glycoprotein IIb/IIIa receptor antagonist approved for acute coronary syndromes.
Bivalirudin — A direct thrombin inhibitor approved for use during percutaneous coronary intervention.
Linaclotide — A guanylate cyclase-C agonist (peptide) approved for chronic idiopathic constipation and IBS-C.
Plecanatide — Similar mechanism to linaclotide; approved for chronic idiopathic constipation and IBS-C.
Calcitonin (salmon, synthetic) — Approved for postmenopausal osteoporosis and Paget's disease. Nasal spray and injection.
Teriparatide and Abaloparatide — Parathyroid hormone-related peptide analogs approved for osteoporosis.
Setmelanotide — A melanocortin-4 receptor agonist approved (2020) for chronic weight management in patients with specific genetic causes of obesity (POMC, PCSK1, LEPR deficiency, and Bardet-Biedl syndrome).
This list is not exhaustive — additional peptide-class drugs exist in oncology, hematology, and rare disease — but it covers the molecules most often encountered in modern peptide-related practice.
A comparison table: FDA-approved vs compounded peptides
| Attribute | FDA-approved peptide drug | Compounded peptide preparation |
|---|---|---|
| Regulatory pathway | NDA or BLA approval by FDA | 503A patient-specific compounding (state-board regulated) or 503B outsourcing (FDA-registered) |
| Pre-market clinical trials | Required (Phases 1–3) | Not required for the compounded preparation itself |
| Labeled indication | Yes, specific to molecule and population | None — preparation is patient-specific based on prescriber's judgment |
| Manufacturer cGMP | Required, FDA-inspected | 503A: USP compounding standards; 503B: cGMP, FDA-inspected |
| Insurance coverage | Often (subject to formulary) | Typically out-of-pocket |
| Prescription required | Yes | Yes |
| Active ingredient (API) | Per approved monograph | Must meet USP grade; sourced from FDA-registered API supplier |
| Post-market surveillance | FAERS adverse event reporting | Adverse events may be reported via state boards and FDA MedWatch |
| Off-label prescribing | Permitted by clinician judgment | Prescription itself is individualized; the preparation is not "off-label" — it is custom |
The two columns are not better-vs-worse. They are different regulatory frameworks, both legal, with different oversight mechanisms and different appropriate uses.
How compounded peptides fit alongside the approved list
Compounding has been part of US pharmacy practice since long before the modern FDA approval framework existed. The Drug Quality and Security Act of 2013 codified two distinct compounding categories:3
Section 503A — A licensed pharmacy compounds a medication for an individual patient based on a valid prescription. The pharmacy is regulated primarily by its state board of pharmacy. The medication is patient-specific. It is not FDA-approved as a product, and it is not required to be — it is a customized preparation made in response to a specific prescription.
Section 503B — An outsourcing facility compounds medications, typically in larger volumes, often for office stock under physician orders. 503B facilities register with the FDA, follow cGMP standards, and are subject to FDA inspection. The medications they produce are also not FDA-approved as products, but the facility itself is FDA-regulated.
Both pathways are legal. Both produce preparations that contain active pharmaceutical ingredients meeting USP grade or equivalent specifications. Neither pathway produces an FDA-approved drug, because neither pathway involves an NDA/BLA.
The clinical practice that uses these pathways is also long-standing. A prescriber identifies a patient with a clinical need, considers approved options, and — if a compounded preparation is appropriate — writes a prescription. The pharmacy verifies the prescription, sources the API from an FDA-registered supplier, prepares the medication, and dispenses it. Quality control includes API testing, sterility validation for sterile preparations, and beyond-use date assignment per USP <797> and <800>.
What the FDA has actually said about compounded GLP-1s
The FDA has issued public statements about compounded semaglutide and tirzepatide, and the framing in those statements is precise:4
- The agency has noted that compounded versions are not FDA-approved.
- The agency has flagged adverse events tied to dosing errors with compounded GLP-1s — most often patient self-administration of the wrong dose volume.
- The agency has not declared compounded GLP-1 prescribing illegal. It has reiterated the existing 503A/503B framework.
- The agency has issued letters and guidance on specific salt forms (e.g., semaglutide sodium) that are not the API form used in approved drugs.
In other words: the FDA distinguishes between (a) the approved branded drug, (b) legitimately compounded preparations using approved-form API under valid prescriptions, and (c) gray-market preparations using non-approved salt forms or sold without prescriptions. The first is FDA-approved. The second is legal but not FDA-approved. The third is the category that draws enforcement.
Where "research peptides" fit (they don't, for therapy)
A separate category — "research-only" or "for research purposes only" peptides — is sold online without prescription, often on websites that include disclaimers that the product is "not for human use." These are not on the list above and do not belong on any list of therapeutic peptides. They:
- Are not FDA-approved
- Are not produced under either 503A or 503B compounding rules
- Have no individualized prescription
- Have no clinical oversight
- Have variable purity, sterility, and identity testing
- Carry contamination risk including endotoxin and microbial impurities
The category exists because of a legal gray area — selling peptides labeled "for research" sidesteps prescription drug requirements at the point of sale. For therapeutic use in humans, this category is not appropriate, full stop.
What this means in practice
If a peptide is being used for a therapeutic purpose in 2026, there are exactly two legitimate regulatory pathways for it:
- An FDA-approved drug — prescribed by a licensed clinician, dispensed by a registered pharmacy. The drug carries an approved indication and an approved dose; off-label use is permitted at clinician judgment.
- A compounded preparation — prescribed by a licensed clinician based on individualized medical necessity, dispensed by a 503A pharmacy or 503B outsourcing facility. The preparation is not FDA-approved as a product. The prescription is real and legal.
Anything else — peptide vials shipped from anonymous websites, "research-only" labels, no prescription involvement — is outside the regulated therapeutic system.
How TelePeptide handles the distinction
TelePeptide programs use both pathways. Where an FDA-approved drug is appropriate and accessible, the prescribing clinician may choose it. Where a compounded preparation is the right fit — most commonly for individualized dosing or for peptides without an approved branded product — the prescription is filled at a licensed 503A pharmacy.
What does not change across either pathway: the prescription comes from a licensed clinician who has reviewed the patient's medical history, goals, and (where indicated) labs. The pharmacy is registered. The patient is monitored. These are the things that make a peptide protocol "prescribed" in the regulatory sense — not which side of the FDA-approval line the molecule falls on.
Compounded medications are prepared by licensed 503A pharmacies. Prescribing decisions are made solely by licensed clinicians based on individual medical necessity. These statements have not been evaluated by the FDA. Compounded medications are not FDA-approved.
Footnotes
-
Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 384, 989–1002. DOI:10.1056/NEJMoa2032183. ↩
-
Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine 387, 205–216. DOI:10.1056/NEJMoa2206038. ↩
-
US Food and Drug Administration. Drug Quality and Security Act (DQSA), Pub. L. 113-54 (2013). https://www.fda.gov/drugs/human-drug-compounding/drug-quality-and-security-act-dqsa ↩
-
US Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss ↩
FAQ
Common questions
Are any peptides actually FDA-approved?
Yes. Several therapeutic peptides have full FDA approval, including semaglutide, tirzepatide, liraglutide, octreotide, teduglutide, bremelanotide, and others. Each carries an approved indication, an approved dose range, and a labeled population. Approval is drug-and-indication specific, not "peptides" as a category.
Is compounded semaglutide FDA-approved?
No. The branded versions of semaglutide are FDA-approved. Compounded semaglutide preparations are individually prescribed and produced by licensed 503A pharmacies in response to a specific patient prescription. Compounded medications are not FDA-approved as products, though they are legal when produced by registered pharmacies under a valid prescription.
What is the difference between a 503A pharmacy and a 503B outsourcing facility?
503A pharmacies compound medications individually for specific patients with specific prescriptions, regulated primarily by state boards. 503B outsourcing facilities compound in larger volumes for office stock under cGMP standards and are regulated directly by the FDA. Both are legal frameworks; both produce non-FDA-approved preparations.
Are growth hormone secretagogues like sermorelin FDA-approved?
Sermorelin acetate had FDA approval as Geref but the branded products were withdrawn from the market — not for safety reasons. It remains available through compounding pharmacies under valid prescription. Other growth hormone secretagogues like ipamorelin and CJC-1295 were never FDA-approved.
How can a clinician prescribe a non-FDA-approved peptide legally?
Federal law permits licensed prescribers to order compounded preparations for individual patients when there is documented medical necessity. The prescription must come from a valid prescriber-patient relationship, and the compounding pharmacy must be appropriately registered. This is distinct from FDA approval but is fully legal.
Why does the distinction between FDA-approved and compounded matter for patients?
FDA-approved drugs have completed Phase 1–3 trials, have a defined indication, a labeled dose, and post-market surveillance. Compounded preparations rely on the active pharmaceutical ingredient meeting USP standards, the pharmacy meeting compounding standards, and the prescriber making an individualized clinical decision. Both pathways exist, but they are not the same standard.
Next Step
Talk to a TelePeptide Clinician
A licensed clinician will review your goals and recommend the right protocol — peptide wellness, recomposition, or supervised weight loss. No insurance, no waiting room.
TelePeptide offers direct-pay telehealth services. All medications are compounded by licensed 503A pharmacies. Prescribing decisions are made solely by licensed clinicians based on individual medical necessity. These statements have not been evaluated by the FDA. Compounded medications are not FDA-approved.